Taji Yoshinori, Kuwahara Takashi, Shikata Satoru, Morimoto Takeshi
Division of General Internal Medicine, Kyoto University Hospital, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.
Clin Exp Nephrol. 2006 Dec;10(4):268-73. doi: 10.1007/s10157-006-0433-8. Epub 2006 Dec 20.
Antiplatelet agents have been widely used in the management of immunoglobulin A (IgA) nephropathy in the Japanese population. To systematically evaluate the effects of antiplatelet agents for IgA nephropathy, we conducted a meta-analysis of the published studies.
Data sources consisted of MEDLINE, EMBASE, the Cochrane Library, Ityu-shi (Japanese medical database), and bibliographies from the studies. The quality of the studies was evaluated from the intention to treat analysis and allocation concealment, as well as by the Jadad method. Meta-analyses were performed on the outcomes of proteinuria and renal function.
Seven articles met the predetermined inclusion criteria. The use of antiplatelet agents showed statistically significant effects on proteinuria and renal function. The pooled risk ratio for proteinuria was 0.61 (95% confidence intervals (CI) 0.39-0.94) and for renal function it was 0.74 (95% CI 0.63-0.87).
Antiplatelet agents resulted in reduced proteinuria and protected renal function in patients with IgA nephropathy. However, studies of high-quality design were rare, and most studies assessed surrogate outcomes. More properly designed studies are needed to reach a definitive assessment of this matter.
抗血小板药物已广泛应用于日本人群免疫球蛋白A(IgA)肾病的治疗。为了系统评估抗血小板药物对IgA肾病的疗效,我们对已发表的研究进行了荟萃分析。
数据来源包括MEDLINE、EMBASE、Cochrane图书馆、Ityu-shi(日本医学数据库)以及各研究的参考文献。通过意向性分析和分配隐藏以及Jadad方法评估研究质量。对蛋白尿和肾功能的结果进行荟萃分析。
七篇文章符合预定的纳入标准。使用抗血小板药物对蛋白尿和肾功能有统计学显著影响。蛋白尿的合并风险比为0.61(95%置信区间(CI)0.39 - 0.94),肾功能的合并风险比为0.74(95% CI 0.63 - 0.87)。
抗血小板药物可减少IgA肾病患者的蛋白尿并保护肾功能。然而,高质量设计的研究很少,大多数研究评估的是替代结局。需要更合理设计的研究来对此问题进行明确评估。